Genesis Healthcare Inc (NYSE:GEN) Director David A. Reis sold 31,361 shares of the business’s stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $1.68, for a total transaction of $52,686.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

David A. Reis also recently made the following trade(s):

  • On Monday, November 12th, David A. Reis sold 43,159 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.68, for a total transaction of $72,507.12.
  • On Thursday, November 8th, David A. Reis sold 55,020 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.67, for a total transaction of $91,883.40.
  • On Tuesday, November 6th, David A. Reis sold 11,147 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.64, for a total transaction of $18,281.08.
  • On Friday, November 2nd, David A. Reis sold 19,456 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.64, for a total transaction of $31,907.84.
  • On Monday, October 29th, David A. Reis sold 7,415 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.64, for a total transaction of $12,160.60.
  • On Wednesday, October 10th, David A. Reis sold 3,502 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.63, for a total transaction of $5,708.26.
  • On Tuesday, September 4th, David A. Reis sold 47,755 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.74, for a total transaction of $83,093.70.
  • On Thursday, August 30th, David A. Reis sold 44,975 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.74, for a total transaction of $78,256.50.
  • On Tuesday, August 28th, David A. Reis sold 64,064 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.72, for a total transaction of $110,190.08.
  • On Friday, August 24th, David A. Reis sold 71,070 shares of Genesis Healthcare stock. The shares were sold at an average price of $1.70, for a total transaction of $120,819.00.

Shares of Genesis Healthcare stock remained flat at $$1.64 during trading on Thursday. 3,403 shares of the stock were exchanged, compared to its average volume of 630,838. Genesis Healthcare Inc has a 12 month low of $0.60 and a 12 month high of $2.86. The stock has a market cap of $276.22 million, a PE ratio of -0.78 and a beta of 0.50.

Genesis Healthcare (NYSE:GEN) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.25). The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period last year, the business earned ($0.34) earnings per share. On average, analysts anticipate that Genesis Healthcare Inc will post -1.39 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. V3 Capital Management L.P. raised its holdings in Genesis Healthcare by 41.4% during the 3rd quarter. V3 Capital Management L.P. now owns 3,563,177 shares of the company’s stock valued at $4,810,000 after buying an additional 1,043,013 shares during the last quarter. First Washington CORP raised its holdings in Genesis Healthcare by 15.5% during the 3rd quarter. First Washington CORP now owns 3,402,937 shares of the company’s stock valued at $4,594,000 after buying an additional 456,520 shares during the last quarter. BlackRock Inc. raised its holdings in Genesis Healthcare by 2.2% during the 3rd quarter. BlackRock Inc. now owns 3,226,485 shares of the company’s stock valued at $4,355,000 after buying an additional 68,168 shares during the last quarter. Columbia Pacific Advisors LLC raised its holdings in Genesis Healthcare by 16.3% during the 3rd quarter. Columbia Pacific Advisors LLC now owns 3,197,455 shares of the company’s stock valued at $5,020,000 after buying an additional 448,962 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Genesis Healthcare by 19.4% during the 3rd quarter. Renaissance Technologies LLC now owns 2,895,611 shares of the company’s stock valued at $3,909,000 after buying an additional 471,411 shares during the last quarter. Institutional investors own 20.12% of the company’s stock.

A number of brokerages have recently issued reports on GEN. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Genesis Healthcare in a research note on Tuesday, August 7th. Credit Suisse Group began coverage on shares of Genesis Healthcare in a research note on Tuesday, October 16th. They issued a “neutral” rating and a $1.75 price objective for the company. Finally, ValuEngine cut shares of Genesis Healthcare from a “buy” rating to a “hold” rating in a research note on Wednesday, July 18th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $3.19.

COPYRIGHT VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/11/15/genesis-healthcare-inc-gen-director-david-a-reis-sells-31361-shares.html.

Genesis Healthcare Company Profile

Genesis Healthcare, Inc, together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy.

See Also: Capital Gains

Insider Buying and Selling by Quarter for Genesis Healthcare (NYSE:GEN)

Receive News & Ratings for Genesis Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genesis Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.